Abstract
BACKGROUND. Radioimmunotherapy with radiolabeled monoclonal antibodies to CD20 produces a high response rate in patients with recurring non-Hodgkin lymphoma (NHL), but the durability of those remissions is not well defined. METHODS. Data on patients with recurring NHL treated with yttrium Y 90 ibritumomab tiuxetan in 4 clinical trials were reviewed to identify patients with a long-term response, defined as a time to progression of 12 months or longer. RESULTS. Long-term responses were seen in 37% (78/211) of patients. At a median follow-up of 53.5 months (range, 12.7-88.9) the median duration of response was 28.1 months and the median time to progression was 29.3 months. A third of these patients had been treated with at least 3 previous therapies, and 37% of them had not responded to their last therapy. The findings in patients with follicular lymphoma (n = 59) were similar to those in the overall population of long-term responders. The estimated overall survival at 5 years was 53% for all patients treated with 90Y ibritumomab tiuxetan and 81% for long-term responders. CONCLUSIONS. A single dose of 90Y ibritumomab tiuxetan can produce durable responses and prolonged overall survival in a substantial number of patients in whom previous therapies have failed.
Original language | English (US) |
---|---|
Pages (from-to) | 1804-1810 |
Number of pages | 7 |
Journal | cancer |
Volume | 109 |
Issue number | 9 |
DOIs | |
State | Published - May 1 2007 |
Funding
This work is supported in part by NASA's Cooperative Agreement NCCI-112; the Hypersonic Aerodynamic Program Grant NAGW-1022 funded jointly by NASA, the Air Force Office of Scientific Research, the Office of Naval Re-search, and the Mars Mission Center funded by NASA Grant NAGW-1331. The authors thank G. A. Bird for his guidance and advice.
Keywords
- Non-Hodgkin lymphoma (NHL)
- Radioimmunotherapy
- Time to progression (TTP)
- Y ibritumomab tiuxetan
ASJC Scopus subject areas
- Oncology
- Cancer Research